Madrid, June 5, 2014. Cross Road Biotech Inversiones Biotecnológicas (CRB Inverbío SGECR SA) is a venture capital management firm that selects innovative projects led by prestigious scientists and entrepreneurs, providing financing, management support and strategic advice.
This private equity manager CRB Inverbío has made the 7th investment with its fund CRB Bio II, one of the largest funds in Spain specialized in the field of Life Sciences. The total investment of the funding round was 4 million euros, to finance Mecwins' growth and global expansion. Mecwins has already employed 4 new people from different parts of the world, 3 of them with a PhD. Right now, Mecwins team is comprised of 11 people, 4 of them doctorate and 6 of them women. The goal of Mecwins after this capital injection is to contribute to the development of biomedical technology in a short-term horizon.
01 MECWINS 01 from Montserrat Calleja on Vimeo.
|
Mecwins is a newly established technological company with a strong focus on R&D. Our activity is highly driven by cutting-edge technology and frontline innovation. Mecwins is developing Nanotechnologies to an advanced stage where they can be applied to diversified fields, from NEMS characterization to clinical analysis. |
|
|
With the collaboration of:
 |
 |
 |
 |
 |
 |
 |
 |
The project IPT-2011-0821-01000 has received funding from Ministerio de Ciencia e Innovación under the program Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2008-2011.
©2011 mecwins All rights reserved.